General News Health

Novartis unit Sandoz recalls a single lot of Losartan tablets


Earlier this week, on Thursday 8th November, Sandoz, a unit of Novartis said that it would recall a single lot of Losartan tablets. The pharmaceutical company is making this recall after it found traces of a probable carcinogen in the blood pressure drug.

Zhejiang Huahai Pharmaceutical Co. Ltd., a Chinese company made this drug. In October, the European Medicines Agency kept the company under high supervision. This was after the agency found that Valsartan, a blood pressure drug contained a probable carcinogen.

The agency also tested and reviewed other ‘sartan’ medicines which included candesartan, valsartan, irbesartan, olmesartan, and losartan. This was testing was done after very low levels of a carcinogen was found in losartan which made by Hetero Labs in India.

Sandoz did not receive any reports of adverse effects related to this recalled lot.

About the author


Jamie Ducharme

Jamie has been in a health writer for Time magazine for the last 1.5 years. She has now joined our team as a health news writer for Kolkata News 24. She brings to the team her vast experience in the health care industry.

Add Comment

Click here to post a comment

Your email address will not be published. Required fields are marked *

Recent Comments